RESMAIN: HDAC inhibitor resminostat for CTCL

Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, discusses findings from the Phase II RESMAIN trial (NCT02953301) evaluating resminostat as a maintenance therapy for patients with advanced-stage mycosis fungoides or Sézary syndrome, two subtypes of cutaneous T-cell lymphoma (CTCL). Prof. Stadler reports that 190 patients will have been recruited to the trial by the end of the year and will final results will be published in 2023. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.